Please assess the completion status of the following clinical trial:

Trial Title: Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Underwent prior radical prostatectomy as local definitive therapy for prostate cancer~* Meets criteria for 1 of the following strata:~  * Has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery~    * Serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease~   * Prior radiotherapy for serologic progression allowed~ * Did not receive any form of androgen blockade therapy within the past 9 months~* No metastatic disease by abdominal/pelvic CT scan and whole-body scan~PATIENT CHARACTERISTICS:~* Able to tolerate CT scanning in the supine position~* No prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia~* No autoimmune disorders~* No acute illness, including active infection requiring antibiotics~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior systemic chemotherapy~* No prior immunological therapy~* No prior single-agent antiandrogen (e.g., high-dose bicalutamide)~* No prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), PC-SPES, or estrogen-containing nutraceuticals~* No concurrent systemic steroid therapy (topical steroids allowed)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).